Leukapheresis

( DrugBank: - / KEGG DRUG: - )


5 diseases
IDDisease name (Link within this page)Number of trials
49Systemic lupus erythematosus1
51Scleroderma1
96Crohn disease2
IDDisease name (Link within this page)Number of trials
284Diamond-Blackfan anemia1
285Fanconi anemia1

49. Systemic lupus erythematosus


Clinical trials : 1,227Drugs : 752 - (DrugBank : 175) / Drug target genes : 130 - Drug target pathways : 207 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

51. Scleroderma


Clinical trials : 639Drugs : 551 - (DrugBank : 157) / Drug target genes : 135 - Drug target pathways : 222 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

96. Crohn disease


Clinical trials : 2,737Drugs : 1,197 - (DrugBank : 240) / Drug target genes : 182 - Drug target pathways : 221 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

284. Diamond-Blackfan anemia


Clinical trials : 39Drugs : 95 - (DrugBank : 35) / Drug target genes : 34 - Drug target pathways : 131 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

285. Fanconi anemia


Clinical trials : 69Drugs : 109 - (DrugBank : 37) / Drug target genes : 45 - Drug target pathways : 169 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries